DIEPPE, New Brunswick, Oct. 30, 2023 – Hexiris Inc. (“Hexiris” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris’s Scientific Committee. Dr. Ahmed is globally renowned for his skills and groundbreaking work in the diagnosis and surgical treatment of highly complex eye diseases including glaucoma and surgical complications. Part of his numerous achievements include pioneering work in innovative glaucoma surgery, developing and coining the term ‘MIGS’ as a new genre of surgical approaches and devices.
“We are truly honoured that Dr. Ahmed has agreed to join Hexiris’s Scientific Committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris. “His vast knowledge and expertise in the field will contribute greatly to our collective efforts to advance the development of Hexiris’ game changing patented MIGS device and process as we move towards the regulatory and commercialization processes.”
“Surgical innovation has always been at the forefront of my passion for ophthalmology, especially pertaining to the development of new devices and technologies. I’m pleased to be joining the Scientific Committee at Hexiris and join in the important work of improving the lives of patients and bringing new solutions and opportunities to ophthalmologists,” said Dr. Ahmed.
Dr. Ike K. Ahmed, MD is a fellowship-trained glaucoma, cataract, and anterior segment surgeon with a practice focus on the surgical management of glaucoma, complex cataract and intraocular lens complications. He is board-certified in ophthalmology in Canada and the USA and is an active member of the Canadian Ophthalmological Society (COS), American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Association for Vision and Research in Ophthalmology (ARVO), International Society of Glaucoma Surgery (ISGS), Canadian Glaucoma Society (CGS), and the American Glaucoma Society (AGS). He is currently Professor at the Department of Ophthalmology and Visual Sciences, University of Utah; Director at the Alan S. Crandall Center for Glaucoma Innovation, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA; a Glaucoma and Advanced Anterior Segment Surgery (GAASS) Fellowship Director at the University of Toronto; Research Director at the Kensington Eye Institute, University of Toronto; Division Head, Ophthalmology, at Trillium Health Partners, Mississauga; and Chief Innovation Officer at Prism Eye Institute, Ontario, Canada.
Dr. Ahmed has published over 200 peer-reviewed papers, as well as numerous book chapters, and has won five film festival awards, six best papers of session, and a poster award at ASCRS, as well as an ESCRS first place video award and AAO “Best of Show” award. He has given over 750 scientific presentations thus far in his career, including 31 visiting professor’s lectures around the world.
Hexiris MIGS Solution
The Hexiris MIGS Solution consists of a specialized medical device and process that is designed to be a safe, fast, easy, and less invasive treatment. The process aims at increasing patient satisfaction, present better patient recovery, and increase the sustainability of a health system under pressure from an ageing population. As a result, the Hexiris MIGS Solution is expected to generate considerable cost benefits for the health system.
First Injectable Ocular Implant
The Hexiris patented ocular implant device is a medical game-changer as the first injectable ocular implant that can be processed under an office slit lamp without the complexity and cost of an operating room.
In-Office MIGS
The Hexiris device will be the first of its generation to take glaucoma surgery out of the surgical unit and make it a simple outpatient procedure. The procedure can be performed with a slit lamp by a certified ophthalmologist.
The first comprehensive solution of its kind
This ground-breaking technology and process will be the first of its kind, as there is no current FDA-approved, ab-externo MIGS devices (injected from the outside of the eye inward) on the market.
About Hexiris
Hexiris Inc. is a pharmaceutical company aimed at advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS). The company’s goal is to provide better access to MIGS for comprehensive ophthalmologists and take glaucoma surgery out of the operating room. To do so, Hexiris is designing and engineering a first-of-its-kind advanced technology device for office-based Minimally Invasive Glaucoma Surgeries (MIGS).
For more information about Hexiris and the innovative Hexiris MIGS solution, please visit the company’s website, at hexiris.ca.
Contact:
Hexiris Inc.
Jean-Philippe Gravel
Chief Operating Officer